David Lucchino

Co-Founder at Frequency Therapeutics, Inc.

David Lucchino

David Lucchino

Co-Founder at Frequency Therapeutics, Inc.

Overview
Career Highlights

Entrega Bio
Frequency Therapeutics, Inc.
Semprus BioSciences Corp.

RelSci Relationships

1154

Number of Boards

14

Birthday

1969

Age

52

Number of Awards

2

Relationships
RelSci Relationships are individuals David Lucchino likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Frequency Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Co-Founder at Lipella Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Candel Therapeutics, Inc.

Relationship likelihood: Strong

Chief, Division of Hematologic Neoplasia at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Co-Founder at Frequency Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at The Multiple Myeloma Research Foundation, Inc.

Relationship likelihood: Strong

Co-Founder at The Multiple Myeloma Research Foundation, Inc.

Relationship likelihood: Strong

Chief Science Officer & Co-Founder at Lipella Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alexandria Real Estate Equities, Inc.

Relationship likelihood: Strong

Paths to David Lucchino
Potential Connections via
Relationship Science
You
David Lucchino
Co-Founder at Frequency Therapeutics, Inc.
Family Members
Extended Family Member
Chairman at The Jimmy Fund

Since its founding in 1948, the Jimmy Fund has raised millions of dollars through thousands of grassroots efforts to help save lives and give hope to cancer patients everywhere.

Education
MBA
Class of 2006

MIT Sloan School of Management is the business school of the Massachusetts Institute of Technology, in Cambridge, Massachusetts, USA. MIT Sloan offers bachelor's, master's, and doctoral programs, as well as non-degree executive education. Its largest program is its full-time MBA, which is one of the most selective in the world, with students from more than 60 countries every year, and ranked #1 in more subjects than any other MBA program.

Class of 1997

The Newhouse School is one of the nation's top schools of communication, preparing students to become leaders in a rapidly changing media landscape.

B.A.
Class of 1991

Denison University is a private, coeducational, and residential liberal arts college in Granville, Ohio, United States, about 30 miles (50 km) east of Columbus, the state capital. Founded in 1831, it is Ohio's second-oldest liberal arts college. Denison is a member of the Five Colleges of Ohio, the Great Lakes Colleges Association, and the North Coast Athletic Conference.

M.S.

Syracuse University (Syracuse, 'Cuse, or SU) is a private research university in Syracuse, New York. The institution's roots can be traced to the Genesee Wesleyan Seminary, founded in 1831 by the Methodist Episcopal Church in Lima, New York. After several years of debate over relocating the college to Syracuse, the university was established in 1870, independent of the college. Since 1920, the university has identified itself as nonsectarian, although it maintains a relationship with The United Methodist Church.

Memberships
Member
Current

American Institute For Medical & Biological Engineering is an American private company located in Washington, DC, that engages in research and development of medical & biological engineering.The company says this about itself: AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. AIMBE’s mission is to recognize excellence, advance the public understanding, and accelerate medical and biological innovation. No other organization can bring together academic, industry, government, and scientific societies to form a highly influential community advancing medical and biological engineering. AIMBE’s mission drives advocacy initiatives into action on Capitol Hill and beyond.

Career History
Co-Founder
2015 - Current

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Co-Founder
2007 - 2012

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification.Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices.

Senior Associate
2005 - 2007

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Boards & Committees
Trustee
Tenure Unconfirmed
Political Donations
$500
2018

Director, Public Affairs at Foley & Lardner LLP

$500
2012

Director, Public Affairs at Foley & Lardner LLP

Transactions
Details Hidden

Semprus BioSciences Corp. raised money in a private placement transaction

Investments
Details Hidden

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification.Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices.

Public Holdings
Restricted data only for RelSci Enterprise users.
Advisors
Senior Advisor

Senior Partner at Puretech Health LLC

Awards & Honors
Alfred P. Sloan Research Fellowship
Boston Business Journal - 40 - Under 40
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David Lucchino. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David Lucchino's profile does not indicate a business or promotional relationship of any kind between RelSci and David Lucchino.